Q4 2022 Results
Existing brands
Company overview
Financial review
Innovation: Pipeline overview
Novartis submission schedule
Supplementary indications for existing brands
2023 priorities
Appendix
Innovation: Clinical trials
Abbreviations
Cardiovascular
Immunology
Neuroscience
Solid tumors
Hematology
Non-core TA project
KisqaliⓇ
2023
ribociclib, LEE011
HR+/HER2- BC (adj)
Lutathera
177 Lu-oxodotreotide
GEP-NET 1L G3
PiqrayⓇ
alpelisib, BYL719
Ovarian cancer
XolairⓇ
omalizumab, IGE025
Food allergy
Y
Jakavi®
2024
ruxolitinib, INC424
Pediatrics Acute GVHD
JakaviⓇ
ruxolitinib, INC424
Pediatrics Chronic GVHD
2025
Cosentyx®
secukinumab, AIN457
Y
GCA
Ly
LeqvioⓇ
KJX839
Ped Hyperlipidemia
ScemblixⓇ
ABL001
CML 1L
ZolgensmaⓇ
AVXS-101 OAV101
SMA IT
O
denosumab
GP2411
BioS
anti RANKL mAb
Adakveo
SEG101
Sickle cell disease, pediatrics
aflibercept
SOK583
BioS
Neovascular age-related macular degeneration
Coartem®
artemether + lumefantrine, COA566
Malaria uncompl., formula for <5kg
AimovigⓇ
erenumab, AMG334
Pediatric Migraine
CosentyxⓇ
secukinumab, AIN457
Lupus Nephritis
KesimptaⓇ2
ofatumumab
Multiple sclerosis, pediatrics
LeqvioⓇ
KJX839
CVRR-LDLC
BeovuⓇ
brolucizumab, RTH258
Diabetic retinopathy
PromactaⓇ
eltrombopag, ETB115
Radiation sickness syndrome
AtecturaⓇ
indacaterol + mometasone, QMF149
Asthma, pediatrics
1. 177 Lu-dotatate in US. 2. Kesimpta and Mayzent: Pediatric study in multiple sclerosis run in conjunction (NEOS).
58 Investor Relations | Q4 2022 Results
≥2026
න
MayzentⓇ 2
siponimod, BAF312
Multiple sclerosis, pediatrics
RydaptⓇ
midostaurin, PKC412
Acute myeloid leukemia, pediatrics
ScemblixⓇ
ABL001
CML, 2L, pediatrics
NOVARTIS | Reimagining MedicineView entire presentation